Unclassified ยท Medical Literature

[Articles] Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies

Authors
Thierry Passeron, Vimal H Prajapati, Raja K Sivamani, Khaled Ezzedine, Nanja van Geel, Iltefat Hamzavi, Amit G Pandya, David Rosmarin, Leihong Xiang, Tamio Suzuki, Seemal Desai, Mehdi Rashighi, Smitha Suravaram, Irina Fish, Xiaofei Hu, Xiaoqiang Wu, Minglu Wang, Yao Yu, Ahmed M Soliman, Heidi S Camp, Henrique D Teixeira, Stavonnie Patterson, Bethanee J Schlosser, Julien Seneschal
Journal
The Lancet
Publication date
2026-08-15
Source
rss_lancet
Original record ID
270233
Summary status
error
Analysis status
error
Original last updated
2026-08-17T07:48:02.000Z

Open original source

Abstract

Upadacitinib 15 mg daily provides clinically meaningful repigmentation of both the face and total body for adults and adolescents with non-segmental vitiligo, with no new safety signals identified.